Jaguar Health Eliminates $5M Note, Cuts $1.7M More Debt via Share Exchanges
JAGX has more than doubled off its 52-week low of $2.35 on elevated volume (3.0× avg).
Summary
Jaguar Health exchanged $6.7 million of secured debt for 730,000 shares, fully cancelling its 2025 Note and reducing its 2021 Note. The deal removes a secured creditor but dilutes existing holders by roughly 50%. A later exchange issued 481,584 shares to reduce the 2021 Note by $3.4 million, leaving about 1,945,542 shares outstanding.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Jaguar Health issued 481,584 shares to Streeterville to reduce the 2021 Note by $3.4 million, leaving about 1,945,542 shares outstanding.
· Benzinga — Additional exchanges brought total debt reduction past $6.7 million, fully retiring the 2025 Streeterville note. JAGX shares rose 47.59% to $10.42.
Key Events · Financing and Capital Events · JAGX
-
Updated · · SEC 8-K
Debt-for-Equity Exchanges with Streeterville
Issued 182,091 shares to reduce the 2021 Note by $1,678,320 and 547,898 shares to reduce the 2025 Note by $5,049,909.26, fully paying and cancelling the 2025 Note. Later issued 481,584 shares to Streeterville to reduce the 2021 Note by $3.4 million.
-
Updated · · SEC 8-K
Secured Debt Eliminated
The $10.8 million 2025 Note is fully paid and cancelled; the 2021 Note balance is reduced by $1.7 million, removing a secured creditor. A later exchange reduced the 2021 Note by an additional $3.4 million.
-
Updated · · SEC 8-K
Dilution Impact
730,000 shares issued against 1,463,958 shares outstanding post-exchange — roughly 50% dilution to existing holders. A later issuance of 481,584 shares left about 1,945,542 shares outstanding.
-
Updated · · SEC 8-K
Share Count Disclosure
Company disclosed 1,463,958 shares outstanding as of September 24, 2026, after the exchanges. A later exchange left about 1,945,542 shares outstanding.
Analysis · JAGX · Life Sciences
Jaguar Health converted $6.7 million of secured debt into equity, fully paying off the $10.8 million 2025 Note and reducing the 2021 Note by $1.7 million. The exchanges remove a secured creditor and reduce cash interest obligations, but they add 730,000 shares to the float — roughly 50% of the 1.46 million shares outstanding after the transaction. For a company with only $3.8 million in cash and a going-concern warning, eliminating secured debt is a meaningful balance-sheet improvement, though the dilution is substantial relative to the tiny share count. A subsequent exchange issued 481,584 shares to reduce the 2021 Note by $3.4 million, leaving about 1,945,542 shares outstanding.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 29% of the 1635 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $7.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $2.35 to $1,280.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.